Powered by OpenAIRE graph
Found an issue? Give us feedback

CROSSJECT

1 Projects, page 1 of 1
  • Funder: French National Research Agency (ANR) Project Code: ANR-23-ASM1-0001
    Funder Contribution: 799,992 EUR

    "Hemorrhagic shock is the result of massive blood loss that can occur as a result of a motor vehicle accident, gunshot wound, domestic accident, or aneurysm rupture. It kills 3 people every minute worldwide. It represents a major public health issue for both the military and civilian sectors. It is the leading cause of preventable death in war casualties (50%) and the second leading cause of death in civilians, causing 1.9 million deaths each year worldwide. Hemorrhagic shock is a therapeutic emergency requiring rapid management. The difficulty when soldiers are injured in operations is access to care and treatment. The particularity for soldiers in operation is to be able to take care of the injured patient quickly with potential difficulties for the management such as the realization of intravenous administration or vascular filling. It is therefore important to propose transportable solutions (light, not too bulky), easily usable in combat situations and intuitive. This solution must allow to maintain the patient's condition for a transport to the place of care (field hospital, hospital center...). The program that we wish to carry out over the next 3 years aims to advance in the drugability of the ""hit"" molecule(s) and to define one or two lead molecules for which we will characterize the pharmacological aspects and derisit their use. We will also validate a functional assembly of our product with the Zeneo® needleless injector system. Objective at the end of the ASMA hErOiSmE² project: a Zeneo® type device containing an OGA inhibitor for the injured person in hemorrhagic shock that can be easily administered in an emergency situation. The consortium we propose for this project builds on a long-standing collaboration between the team of B. Lauzier (researcher, cardiac physiology) and A. Tessier (researcher, synthetic chemistry). Their expertise has been reinforced for a few years by the group of N Prat (physician, IRBA researcher) who brings his knowledge of the physiopathology of war trauma and large mammal (pig) models. This association of 3 academic research groups is completed by two companies: the company Crossject which is specialized in the development of solutions for intramuscular injection without needle. Finally, the company IDD, specialized since 2003 in a wide range of services such as regulatory assistance and assistance for MA applications as well as medical device certifications. A well-established partner of the French Army, IDD will bring its expertise in project management and strategic development (CMC, non-clinical, clinical) as well as in regulatory strategy. In conclusion, the hErOiSmE² project should allow to reach a TRL 6 maturity level (validation in a representative environment of a representative model or a prototype system) - validation of the Zeneo device and basic pharmacology in a large mammalian animal model."

    more_vert

Do the share buttons not appear? Please make sure, any blocking addon is disabled, and then reload the page.

Content report
No reports available
Funder report
No option selected
arrow_drop_down

Do you wish to download a CSV file? Note that this process may take a while.

There was an error in csv downloading. Please try again later.